Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 8,611 matching trials from the live ClinicalTrials.gov search.

Filters: Indianapolis, Indiana Clear all

Conditions: Intracranial Meningioma
Interventions: [177Lu]Lu-DOTATATE, Standard of Care treatments; Drug · Other
Lead sponsor: RTOG Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 17
States / cities: Irvine, California • La Jolla, California • New Haven, Connecticut + 13 more

Conditions: Premature Birth
Interventions: Low dose aspirin, Placebo; Drug
Lead sponsor: NICHD Global Network for Women's and Children's Health; Network
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 11,976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 7
States / cities: Birmingham, Alabama • Denver, Colorado • Indianapolis, Indiana + 4 more

Conditions: Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
Interventions: Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Patient Observation; Drug · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 932
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 639 more

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: Up to 6 Months
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 22
States / cities: St. Petersburg, Florida • Boise, Idaho • Chicago, Illinois + 19 more

Conditions: Rheumatoid Arthritis
Interventions: LY2127399, Placebo Q4W, Placebo Q2W; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 110
States / cities: Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 107 more

Conditions: Atopic Dermatitis
Interventions: Tapinarof cream, 1%, Vehicle Cream; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 3 Months to 23 Months
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 36
States / cities: Birmingham, Alabama • Bryant, Arkansas • Los Angeles, California + 32 more

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: pemetrexed disodium; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 18
States / cities: Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 15 more

Conditions: Solid Tumors
Interventions: M3541, Palliative Radiotherapy (RT); Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Indianapolis, Indiana • St Louis, Missouri • Hackensack, New Jersey + 2 more

Conditions: Schizophrenia and Related Disorders, Sleep Disturbance
Interventions: SPARK Healthy Sleep; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Atrial Fibrillation
Interventions: Dronedarone; Drug
Lead sponsor: American Heart Association; Other
Eligibility: 21 Years and older
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 103
States / cities: Fairhope, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 78 more

Conditions: Urothelial Carcinoma
Interventions: Gemcitabine, Cisplatin, Ipilimumab; Drug
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 8
States / cities: Duarte, California • Goshen, Indiana • Indianapolis, Indiana + 4 more

Conditions: Syphilis
Interventions: Benzathine Penicillin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 10
States / cities: Birmingham, Alabama • Atlanta, Georgia • Indianapolis, Indiana + 7 more

Conditions: Sleep Apnea, Obstructive
Interventions: Aspire Medical Advance System; Device
Lead sponsor: Aspire Medical; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Cincinnati, Ohio + 1 more

Conditions: Colorectal Cancer
Interventions: Erlotinib (aka Tarceva or OSI-774), Bevacizumab (aka Avastin or Rhu MAb VEGF); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 3
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Dallas, Texas

Conditions: AL Amyloidosis
Interventions: NEOD001, Placebo; Drug
Lead sponsor: Prothena Biosciences Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 19
States / cities: Duarte, California • Stanford, California • Denver, Colorado + 15 more

Conditions: Brain and Central Nervous System Tumors
Interventions: carboplatin, cisplatin, cyclophosphamide, etoposide, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: Up to 10 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 29
States / cities: Phoenix, Arizona • Loma Linda, California • Long Beach, California + 21 more

Conditions: Surgical Site Infection, Unplanned Fracture-Related Reoperation, Open Appendicular Fracture, Closed Lower Extremity Fracture, Pelvic Fracture
Interventions: DuraPrep, ChloraPrep; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 8,485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 24
States / cities: Irvine, California • Los Angeles, California • San Jose, California + 20 more

Conditions: Hyperlipidemia
Interventions: Enlicitide, Rosuvastatin, Placebo for Enlicitide, Placebo for Rosuvastatin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 35
States / cities: Birmingham, Alabama • Foley, Alabama • Phoenix, Arizona + 30 more

Conditions: Gastroschisis
Interventions: 35-week delivery, 38-week delivery; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 38
States / cities: Phoenix, Arizona • Loma Linda, California • Stanford, California + 30 more

Conditions: Influenza, Human
Interventions: zanamivir aqueous solution; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 33 more

Conditions: Von Willebrand Disease
Interventions: Recombinant von Willebrand factor (rVWF), Placebo, Recombinant factor VIIII (rFVIII); Biological · Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 10
States / cities: Sacramento, California • Miami, Florida • Peoria, Illinois + 7 more

Conditions: Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
Interventions: Alisertib, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 50
States / cities: Hartford, Connecticut • New Britain, Connecticut • Orlando, Florida + 37 more

Conditions: NODULOCYSTIC ACNE
Interventions: Finasteride 23.5 mg tablets, Finasteride 33.5 mg tablets, Placebo tablets; Drug
Lead sponsor: Elorac, Inc.; Industry
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 25
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 22 more

Conditions: Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma, Pineal Region Germinoma, Suprasellar Germinoma, Thalamic Germinoma
Interventions: 3-Dimensional Conformal Proton Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Carboplatin, Etoposide, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Lumbar Puncture, Magnetic Resonance Imaging, Questionnaire Administration, Surgical Procedure; Radiation · Procedure · Drug + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 29 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 97
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 76 more

Search by objective public record fields.

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)

A Study in Participants With Rheumatoid Arthritis

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors

M3541 in Combination With Radiotherapy in Solid Tumors

SPARK Healthy Sleep

Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

Phase 4 Comparative Trial of Benzathine Penicillin G for Treatment of Early Syphilis in Subjects With or Without HIV Infection

The Advance Trial. Tongue Advancement for Obstructive Sleep Apnea: An Evaluation of the Aspire Medical Advance System

Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors

Pre-operative Alcohol Skin Solutions in Fractured Extremities

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Gastroschisis Outcomes of Delivery (GOOD) Study

Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

Finasteride Treatment of Severe Nodulocystic Acne

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma